TET2 and myelodysplastic syndrome: Delhommeau and colleages then sequenced TET2 in patient tumor samples, becoming the first group to identify TET2 mutations in multiple myeloid neoplasms, including MDS (19%), MPNs (12%–14%), and sAML (24%).